PFF Help Center(844) 825-5733

To navigate the following site navigation expect to utilize the tab key to move through items sequentially. The spacebar or enter keys can be utilized to interact with items that open sub-navigation.

The next tab will be the search box toggle. Hit enter to open the search, focus will automatically shift to the search bar. Type a letter into the search input and suggested results will appear.

Drug

Zinc and Nicotinamide Riboside

Status:

Phase 2

Condition:

Idiopathic Pulmonary Fibrosis

Intervention Type:

Oral Drug

Funder Type:

Organization | University

Drug Details

Zinc and nicotinamide riboside target the lung repair mechanism through boosting the ZIP8/SIRT1/NAD+ pathway, which promotes tissue regeneration, reduces scarring, and combats oxidative stress. This is a complementary approach to slow fibrosis and has potential to reverse damage by activating lung stem cells.

This study is a decentralized, double-blind, randomized phase 2 study on the safety and efficacy of zinc and nicotinamide riboside in participants with idiopathic pulmonary fibrosis (IPF).

Find a Clinical Trial